Bavarian will use own money to start RSV trials, but is still seeking a partner

After several discussions with the FDA, Bavarian Nordic has finally finished designing the study of its RSV vaccine and will start a 12,000 person phase III study in 2021.

Photo: PR / Bavarian Nordic

As the end of the year approaches, Bavarian Nordic has started to look towards 2020, and has revealed two central points of next year's work: the purchase of two new vaccines from Glaxosmithkline and a timeline for the company's large phase III test of a vaccine against airway virus RSV.

The timeline for the RSV vaccine has been particularly long-awaited, as Bavarian's negotiations with the American medicine authorities over the design of the study have dragged out, and the final agreement has come much later than expected.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs